Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTD

Partner with us and transform your program

DISCOVER YOUR NEXT BREAKTHROUGH WITH PSYCHOGENICS

Get Started